Aptorum Group Limited
APMHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and. At a $1.7M market cap, Aptorum Group Limited ranks as a micro-cap company within healthcare. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa.
Market Cap
$1.7M
Beta
0.17
P/E (TTM)
—
P/E (Fwd)
-0.99
EPS (TTM)
$-1.90
EPS (Fwd)
$-0.71
ROE
-10.8%
ROA
-6.5%
Cash
$3.5M
Total Debt
$3.4M
Free CF
-$1.1M
52W Change
-59.9%
Annual Financials
Cash vs Debt
Where APM stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, APM finished 11.96% below its 150-day moving average ($0.92) and 25.69% below its 200-day moving average ($1.09). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is APM overbought or oversold?
At the July 15, 2026 close, APM's RSI(14) was 46.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $3.5M in cash and $3.4M in debt, APM maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$1.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -10.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $1.3M (2022) to $0 (2025), a 100% decline worth watching.
APM's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing APM's risk profile alongside its fundamentals and technical indicators provides a more complete picture.